14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Tumor-Reprogrammed Stromal BCAT1 Fuels Branched Chain Ketoacid Dependency in Stromal-Rich PDAC Tumors

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          SUMMARY

          Branched chain amino acids (BCAAs) supply both carbon and nitrogen in pancreatic cancers, and their increased levels have been associated with increased risk of pancreatic ductal adenocarcinomas (PDACs). It remains unclear, however, how stromal cells regulate BCAA metabolism in PDAC cells and how mutualistic determinants control BCAA metabolism in the tumor milieu. Here we show distinct catabolic, oxidative, and protein turnover fluxes between cancer-associated fibroblasts (CAFs) and cancer cells and a marked branched chain ketoacid (BCKA)-reliance in PDAC cells in stroma-rich tumors. We report that cancer-induced stromal reprogramming fuels this BCKA demand. The TGF-β/SMAD5 axis directly targets BCAT1 in CAFs and dictates internalization of the extracellular matrix from the tumor microenvironment to supply amino acid precursors for BCKA secretion by CAFs. The in vitro results were corroborated with human patient-derived circulating tumor cells (CTCs) and PDAC tissue slices. Our findings reveal therapeutically actionable targets in pancreatic stromal and cancer cells.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: not found

          Proteomics. Tissue-based map of the human proteome.

          Resolving the molecular details of proteome variation in the different tissues and organs of the human body will greatly increase our knowledge of human biology and disease. Here, we present a map of the human tissue proteome based on an integrated omics approach that involves quantitative transcriptomics at the tissue and organ level, combined with tissue microarray-based immunohistochemistry, to achieve spatial localization of proteins down to the single-cell level. Our tissue-based analysis detected more than 90% of the putative protein-coding genes. We used this approach to explore the human secretome, the membrane proteome, the druggable proteome, the cancer proteome, and the metabolic functions in 32 different tissues and organs. All the data are integrated in an interactive Web-based database that allows exploration of individual proteins, as well as navigation of global expression patterns, in all major tissues and organs in the human body. Copyright © 2015, American Association for the Advancement of Science.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Integrating single-cell transcriptomic data across different conditions, technologies, and species

            Computational single-cell RNA-seq (scRNA-seq) methods have been successfully applied to experiments representing a single condition, technology, or species to discover and define cellular phenotypes. However, identifying subpopulations of cells that are present across multiple data sets remains challenging. Here, we introduce an analytical strategy for integrating scRNA-seq data sets based on common sources of variation, enabling the identification of shared populations across data sets and downstream comparative analysis. We apply this approach, implemented in our R toolkit Seurat (http://satijalab.org/seurat/), to align scRNA-seq data sets of peripheral blood mononuclear cells under resting and stimulated conditions, hematopoietic progenitors sequenced using two profiling technologies, and pancreatic cell 'atlases' generated from human and mouse islets. In each case, we learn distinct or transitional cell states jointly across data sets, while boosting statistical power through integrated analysis. Our approach facilitates general comparisons of scRNA-seq data sets, potentially deepening our understanding of how distinct cell states respond to perturbation, disease, and evolution.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Genomic analyses identify molecular subtypes of pancreatic cancer.

              Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours are enriched for TP53 and KDM6A mutations, upregulation of the TP63∆N transcriptional network, hypermethylation of pancreatic endodermal cell-fate determining genes and have a poor prognosis. Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contained upregulated immune networks including pathways involved in acquired immune suppression. These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development.
                Bookmark

                Author and article information

                Journal
                101736592
                48119
                Nat Metab
                Nat Metab
                Nature metabolism
                2522-5812
                31 May 2020
                06 July 2020
                August 2020
                06 January 2021
                : 2
                : 8
                : 775-792
                Affiliations
                [1 ]Laboratory for Systems Biology of Human Diseases, University of Michigan, Ann Arbor, MI, 48109, USA
                [2 ]Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA
                [3 ]Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA
                [4 ]Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA
                [5 ]Department of Cancer Biology, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA
                [6 ]Department of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA
                [7 ]Rogel Cancer Center, University of Michigan, Ann Arbor, MI, 48109, USA
                [8 ]Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, 97201, USA
                [9 ]Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78245, USA
                [10 ]Department of Translational Molecular Pathology and Sheikh Ahmed Center for Pancreatic Cancer Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA
                [11 ]Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA
                [12 ]Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, 48109, USA
                Author notes
                [* ]To whom correspondence should be addressed: Deepak Nagrath, PhD, Department of Biomedical Engineering, NCRC Bldg 28, Room 3048W, University of Michigan, Ann Arbor, MI, 48109, dnagrath@ 123456umich.edu

                AUTHOR CONTRIBUTIONS

                Z.Z., A.A. and D.N. designed the experiments. Z.Z. performed most experiments. A.A. and O.A. developed and performed all of the bioinformatics analysis. S.O. and S.N. collected PDAC patient samples, isolated, characterized and developed CTC lines using microfluidics Labyrinth chip. A.A., O.A., N.M., and A.Mi developed and performed all metabolic and mass spectrometry assays. P.P. and T.W.L. assisted with assays. J.F.B. and E.C. provided CAFs and helped with stromal characterization, J.S. helped with patient tissue and IHC, V.G. and V.S. collected patient blood for CTC analysis, M.H.S. provided CAFs and helped with stromal characterization, A.M.P. helped with proteasomal analysis, A.Ma analyzed the data and helped in clinical correlations, M.A.M. and T.S.L. provided tissue slices and helped in designing various experiments. Z.Z., A.A. and D.N. wrote the manuscript with input from co-authors.

                Article
                NIHMS1599206
                10.1038/s42255-020-0226-5
                7438275
                32694827
                a118371e-7103-4cb3-83ee-db441c5488bd

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Comments

                Comment on this article